$IFRX宣布美国第2期ANCA相关性血管炎IXPLORE研究的Vilobelimab的阳性结果为$IFRX Announces Positive Topline Results for Vilobelimab from the U.S. Phase 2 ANCA-Associated Vasculitis IXPLORE Study
2021-04-06 成本 现价 浮动收益 Histogenics Corporation(OCGN) 0.5338 6.35 +1,091.49% I think Covaxin is very difficult to get fda eua approach to USA before May.The important case is the phase 3 hasn't U.S clinical trials. so I just sell off the last position.